Gilead Sciences, Inc. $GILD Stock Sold by MH & Associates Securities Management Corp ADV

MH & Associates Securities Management Corp ADV lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 32.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 17,668 shares of the biopharmaceutical company’s stock after selling 8,493 shares during the period. Gilead Sciences makes up about 2.3% of MH & Associates Securities Management Corp ADV’s holdings, making the stock its 22nd biggest position. MH & Associates Securities Management Corp ADV’s holdings in Gilead Sciences were worth $2,633,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of GILD. Persistent Asset Partners Ltd purchased a new stake in shares of Gilead Sciences in the second quarter worth $25,000. Kimelman & Baird LLC purchased a new position in Gilead Sciences during the second quarter worth about $25,000. PFS Partners LLC grew its position in Gilead Sciences by 101.1% during the third quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 96 shares in the last quarter. Laurel Wealth Advisors LLC purchased a new position in Gilead Sciences during the third quarter worth about $29,000. Finally, Wiser Advisor Group LLC bought a new position in Gilead Sciences in the 2nd quarter worth about $30,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

GILD opened at $174.48 on Thursday. The company has a current ratio of 1.38, a quick ratio of 0.95 and a debt-to-equity ratio of 1.84. The stock has a market capitalization of $216.41 billion, a P/E ratio of -55.22 and a beta of 0.35. The stock has a 50-day moving average price of $152.29 and a 200-day moving average price of $140.52. Gilead Sciences, Inc. has a 12-month low of $116.88 and a 12-month high of $175.65.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. The company had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. Gilead Sciences’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.47 EPS. Equities analysts predict that Gilead Sciences, Inc. will post -1.07 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be given a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently -103.80%.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: DZ Bank raised its price target on Gilead to $191 from $167, signaling increased confidence in the stock’s prospects. DZ Bank Adjusts Price Target on Gilead Sciences to $191 From $167
• Positive Sentiment: Gilead and its Kite subsidiary plan 23 presentations, including seven oral presentations, at the December ASH meeting. The breadth of planned data across the pipeline and portfolio may draw investor attention to potential growth drivers. Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026
• Positive Sentiment: BioNTech and Gilead are advancing a global Phase 3 trial combining BioNTech’s pumitamig with Gilead’s cancer drug Trodelvy (sacituzumab govitecan) for metastatic triple-negative breast cancer. The collaboration expands the potential reach of Gilead’s oncology portfolio, though trial results remain to come. BioNTech Enters First Global Phase 3 Trial for New Breast Cancer Combo
• Neutral Sentiment: Gilead’s GS-1206 cancer study continues to advance, but investors are still waiting for early efficacy signals; the update did not provide results that establish the drug’s potential. Gilead’s GS-1206 Cancer Trial Advances as Investors Watch for Early Signals
• Negative Sentiment: Put-option purchases were unusually elevated, which may reflect increased hedging or bearish positioning, though options activity alone does not confirm a negative outlook.
• Negative Sentiment: CEO Daniel O’Day disclosed recent stock sales under a pre-arranged Rule 10b5-1 plan. The planned nature of the sales may limit their significance, but insider selling can still weigh on sentiment.

Analysts Set New Price Targets

GILD has been the topic of several recent analyst reports. Royal Bank Of Canada raised their price target on Gilead Sciences from $126.00 to $131.00 and gave the company a “sector perform” rating in a report on Friday, October 30th. Citigroup boosted their price objective on Gilead Sciences from $165.00 to $188.00 and gave the stock a “buy” rating in a report on Friday, October 30th. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Zacks Research downgraded shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 29th. Finally, Cantor Fitzgerald lifted their target price on shares of Gilead Sciences from $155.00 to $175.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $170.15.

Insiders Place Their Bets

In other news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the sale, the director owned 10,066 shares of the company’s stock, valued at approximately $1,459,771.32. This represents a 33.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the firm’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the completion of the sale, the director directly owned 12,894 shares in the company, valued at approximately $1,916,306.28. This trade represents a 58.26% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 126,881 shares of company stock valued at $19,252,455 over the last three months. 0.30% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.